Clinical Trials Logo

Clinical Trial Summary

This is a phase I, multicenter, open-label dose escalation and expansion study to evaluate genakumab alone and in combination with tislelizumab in adult patients with advanced solid malignancies.


Clinical Trial Description

The study is divided into two parts: Part I: Part Ia: Two dose groups are planned, which are genakumab 200 mg, 300 mg. Genakumab is administered subcutaneously once every three weeks. Part Ib: Three dose groups are planned, which are genakumab 100 mg plus tislelizumab 200 mg, genakumab 200 mg plus tislelizumab 200 mg, genakumab 300 mg plus tislelizumab 200 mg. Genakumab is administered subcutaneously once every three weeks. Tislelizumab is administered intravenously following genakumab on D1 of every cycle. The study process of Part I includes the screening period (4 weeks), the observation period of dose-limiting toxicity (DLT) evaluation (defined as 3 weeks after first dosing), continuous dosing period (dosing once every 3 weeks until the discontinuation criteria are met), safety follow-up period after discontinuation (28±5 days after last dosing) and progression-free survival follow-up period after discontinuation (once every 6 weeks, until the progression-free survival follow-up endpoint). Part II: The sponsor and the investigator will choose one dose level as RP2D based on the totality of safety, PK, PD, and preliminary efficacy data from Part I. Additional 90 patients (30 patients for each cohort) will be treated at this dose level. The administration method is the same as that in Part I while without DLT observation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05441046
Study type Interventional
Source GeneScience Pharmaceuticals Co., Ltd.
Contact Shuaishuai Zhang, MD
Phone 86 21 6087 1690
Email zhangshuaishuai@gensci-china.com
Status Recruiting
Phase Phase 1
Start date June 7, 2022
Completion date March 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05539677 - Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Completed NCT05594147 - An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
Not yet recruiting NCT06082557 - A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients Phase 1/Phase 2
Not yet recruiting NCT05508620 - A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors Phase 1
Completed NCT02902237 - tTF-NGR Phase I Study Phase 1
Completed NCT03205176 - AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas Phase 1
Completed NCT01765790 - Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors Phase 1
Completed NCT05930457 - Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors Phase 1
Active, not recruiting NCT01694472 - Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors Phase 1
Completed NCT01391533 - Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors Phase 1
Completed NCT00516438 - Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan Phase 1
Completed NCT01519817 - Cancer Vaccine Targeting Brachyury Protein in Tumors Phase 1
Recruiting NCT03739827 - Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Recruiting NCT05579275 - Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors Early Phase 1
Completed NCT05814835 - First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors Phase 1
Recruiting NCT02421380 - Characterization of Hyperpolarized Pyruvate MRI Reproducibility N/A
Completed NCT02805166 - PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Phase 4